ArticleCancer science2026
JI-CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7-H3.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Melanoma is the most lethal form of skin cancer, with a significantly poor prognosis after metastasis. The BRAF inhibitor dabrafenib increases response rates and overall survival (OS) in advanced-stage melanoma; however, most patients develop resistance rapidly, highlighting the need for improved combination regimens. This study investigated the therapeutic efficacy of JI-CJ002, an herbal extract consisting of Angelica gigas, Aconitum carmichaeli, and Zingiber officinale blended in a 2:1:3 (w/w) ratio, and assessed the combined antineoplastic effects of JI-CJ002 with dabrafenib in melanoma. JI-CJ002 suppressed epithelial-mesenchymal transition (EMT), invasion, and melanin synthesis, and these effects were maintained in combination with dabrafenib. The combination treatment was associated with reduced B7-H3 expression, along with inhibition of signaling pathways implicated in melanoma progression, including JAK2/STAT3, PI3K/AKT/mTOR, and NF-κB. Efficacy of the combination regimen was further evaluated in an A375 xenograft murine model. In vivo studies demonstrated that combination therapy reduced tumor volume without causing systemic toxicity, accompanied by decreased proliferation markers (PCNA and Ki-67), increased apoptotic marker (cleaved caspase-3), and decreased B7-H3 expression in tumor tissues. These results suggest that JI-CJ002 may enhance the antitumor activity of dabrafenib, accompanied by modulation of oncogenic pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.